Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Lenvatinib in Previously Treated Solid Tumors (LEAP-005)
NCT03797326Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2019
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 17
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in triple-negative breast cancer (TNBC), ovarian cancer, gastric cancer (GC), colorectal cancer (CRC), glioblastoma (GBM), sponsored by Merck & Co.. Started Feb 2019; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
triple-negative breast cancer (TNBC)ovarian cancergastric cancer (GC)colorectal cancer (CRC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03797326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03797326.